Infusion Therapies And Advanced Systems Will Shape Healthcare Outcomes

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

26 May 25

Updated

01 Dec 25

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

-8.5%

7D

-4.6%

Loading

1Y

-8.5%

7D

-4.6%

You can edit this narrative until Dec 2 7:10 PM. Then, changes will post as Updates.

Author's Valuation

US$180.8321.3% undervalued

AnalystConsensusTarget Fair Value

Shared on 01 Dec 25

ICUI: Portfolio Transformation Will Drive Share Performance Following Recent Joint Venture

ICU Medical’s analyst price target has been raised by $8 to $153, as analysts cite ongoing portfolio transformation and strategic business moves as key drivers for improved valuation. Analyst Commentary Recent analyst discussions have focused on ICU Medical's ongoing portfolio transformation and its potential impacts on company performance.

Shared on 17 Nov 25

Fair value Increased 2.46%

ICUI: Vital Care Portfolio Moves Will Unlock Greater Shareholder Value

ICU Medical’s fair value estimate has been revised upward from $176.50 to $180.83 per share. This change reflects analysts’ increased optimism on growth and profitability following recent portfolio transformations and ongoing strategic evaluations.

Shared on 27 Aug 25

Fair value Decreased 3.45%

The reduction in ICU Medical’s price target reflects weaker growth expectations, as consensus revenue projections have turned negative, while a lower future P/E ratio suggests diminished earnings optimism; accordingly, the fair value estimate has decreased from $182.80 to $176.50. What's in the News ICU Medical raised its 2025 GAAP net loss guidance, now expecting a loss between $43 million and $35 million, with GAAP diluted loss per share between $1.68 and $1.38.